登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 29 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 29
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心广东医科大学附属医院Affiliated Hospital of Guangdong Medical University湛江医院页面
- 研究中心江南大学附属医院Affiliated Hospital of Jiangnan University无锡医院页面
- 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
- 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
- 研究中心海军军医大学第一附属医院(长海医院)Changhai Hospital上海医院页面
- 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
- 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
- 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
- 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
- 研究中心南方医科大学南方医院Nanfang Hospital广州医院页面
- 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心安徽医科大学第二附属医院Second Affiliated Hospital of Anhui Medical University合肥医院页面
- 研究中心南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心河北医科大学第二医院Second Hospital of Hebei Medical University石家庄医院页面
- 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
- 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
- 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
- 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
- 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面
- 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
- 研究中心四川大学华西医院West China Hospital成都医院页面
- 研究中心襄阳市中心医院Xiangyang Central Hospital襄阳医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06170788,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed diagnosis of squamous or nonsquamous NSCLC
入选标准第 1 条
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor Note: Prior treatment with an anti-PD-1, anti-PD- L1, or anti-PD-L2 agent in the neoadjuvant or adjuvant setting for nonmetastatic resectable NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.
排除标准第 7 条
Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
排除标准第 8 条
Received radiation therapy to the lung that is >30 Gy within 6 months of start of study intervention.
排除标准第 9 条
Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
排除标准第 10 条
An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization.
入选标准第 4 条
Confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), or proto-oncogene tyrosine-protein kinase ROS (ROS1-) directed therapy is not indicated as primary therapy
入选标准第 2 条
Known additional malignancy that is progressing or has required active treatment within the past 3 years.
排除标准第 13 条
Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
排除标准第 21 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06170788,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histologically or cytologically confirmed diagnosis of squamous or nonsquamous NSCLC Confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), or proto-oncogene tyrosine-protein kinase ROS (ROS1-) directed therapy is not indicated as primary therapy Provided tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥50% of tumor cells as assessed by an immunohistochemistry (IHC) central laboratory An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization. A life expectancy of at least 3 months. Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)排除标准:Exclusion Criteria:
Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements. Has Grade ≥2 peripheral neuropathy. History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing. Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea). Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention. Received prior systemic anticancer therapy for their metastatic NSCLC. Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor Note: Prior treatment with an anti-PD-1, anti-PD- L1, or anti-PD-L2 agent in the neoadjuvant or adjuvant setting for nonmetastatic resectable NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC. Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization. Received radiation therapy to the lung that is >30 Gy within 6 months of start of study intervention. Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids. Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy Known additional malignancy that is progressing or has required active treatment within the past 3 years. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Known intolerance to sacituzumab tirumotecan or pembrolizumab and/or any of their excipients; for pembrolizumab, severe hypersensitivity (≥Grade 3) is exclusionary. Known hypersensitivity to sacituzumab tirumotecan or other biologic therapy. Active autoimmune disease that has required systemic treatment in the past 2 years. History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD. Active infection requiring systemic therapy Concurrent active Hepatitis B and Hepatitis C virus infection. Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. History of allogeneic tissue/solid organ transplant. Requires treatment with a strong inhibitor or inducer of Cytochrome P450 3A4 (CYP3A4) at least 14 days before the first dose of study intervention and throughout the study.
引自 ClinicalTrials.gov, NCT06170788, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06170788,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。